Pharmaceutical and Biopharmaceutical Manufacturing: Understanding Your Process Series
The U.S. FDA plans to take a risk-based approach to biomanufacturing inspection and changes are expected very soon. With regulatory expectations and the impending changes anticipated in 21CFR 600 in June 2018, now is the time to get up to date on managing risk to safely produce healthcare products!
In order to help you, we have gathered chapters from our most successful risk-based texts. These convenient, electronic texts define risk, discuss hazards and risks, provide tools to help you evaluate risk, and develop effective strategies for dealing with risk.
Written by subject matter experts, each text contains practical applications, an extensive list of international regulations for reference, and suggested PDA Technical Reports and books for further guidance.
Risk Management Library Volume 7, Risk Problem Solvers: Inadequate Facilities, Procedures and Process Control
This publication is taken from the book: Lessons of Failure: When Things Go Wrong In Pharmaceutical Manufacturing published in 2015.
This volume describes 24 problems and offers solutions regarding everything from bioburden contamination in a contained water system to filter integrity, customer complaints, process control failures and many more real-world problems that arose and were solved with adequate investigation.
Available to download. Prior to purchase please view the download instructions and Terms of Usage
Format: PDF (1 file 1.10 MB)
Table of Contents:
Click here to download >>>Detailed Table of Contents
- White Precipitate 3 (Chapter excerpted from Lessons of Failure: When Things Go Wrong In Pharmaceutical Manufacturing, Chapter 5)
- I've got it!...You take it! (Chapter excerpted from Chapter 8)
- Bioburden Contamination in a Contained Water System (Chapter excerpted from Chapter 12)
- Cleaning Validation (Chapter excerpted from Chapter 15)
- Material Decontamination Failure (Chapter excerpted from Chapter 17)
- An Aseptic Processing Intervention to Avoid (Chapter excerpted from Chapter 21)
- It's a Like for Like Replacement (Chapter excerpted from Chapter 22)
- Not Invented Here I (Chapter excerpted from Chapter 24)
- Bury my Heart in the SOP (Chapter excerpted from Chapter 25)
- The Complaint is Unjustified (Chapter excerpted from Chapter 26)
- The Nitrogen Delivery Wasn't Made: Or Was It? (Chapter excerpted from Chapter 29)
- Used the Right Gas? Are You Sure? (Chapter excerpted from Chapter 31)
- How to Train a Body Builder (Chapter excerpted from Chapter 36)
- Viral Contamination of Bioreactors used to Produce Enzyme Replacement Therapy (Chapter excerpted from Chapter 37)
- Fungal Problems Sideline Vaccine Manufacturer (Chapter excerpted from Chapter 40)
- Blue Sky (Chapter excerpted from Chapter 41)
- Technology Transfer (Chapter excerpted from Chapter 47)
- You See What You Want to See (Chapter excerpted from Chapter 49)
- Not Invented Here 3 (Chapter excerpted from Chapter 55)
- A 12-step Program for CGMPs: Lessons of a Pharmaceutical Lifetime (Chapter excerpted from Chapter 56)
- Is Anybody Listening? (Chapter excerpted from Chapter 57)
- The Troublesome Media Fill (Chapter excerpted from Chapter 61)
- Contamination of an Aseptic Fill (Chapter excerpted from Chapter 63)
- The Green Blob (Chapter excerpted from Chapter 65)
Current Regulations, Guidances, Technical Reports and Texts Useful for Further Reference.
About the Editors
Russel E. Madsen is President of The Williamsburg Group, LLC, providing expert pharmaceutical consulting services including CGMP compliance, quality systems, aseptic processing and sterilization, sterilizing filtration, design review, due diligence, and regulatory liaison. Prior to forming The Williamsburg Group, he had served PDA as Acting President and was Senior VP Science and Technology. Before joining PDA, he was employed by Bristol-Myers Squibb Company as Director, Technical Services, providing technical and general consulting services to Bristol-Myers Squibb operations, worldwide. He is Vice-Chairman of ASTM E55.03 General Pharmaceutical Standards, a member of the USP Microbiology Expert Committee, Chairman of the USP Visual Inspection of Parenterals Expert Panel, a member of Pharmaceutical Technology's Editorial Advisory Board, and an Honorary Member of PDA. He holds a Bachelor of Science degree from St. Lawrence University and a Master of Science degree from Rensselaer Polytechnic Institute.
Maik W. Jornitz is is the Founder and Principal Consultant of BioProcess Resources LLC. BioProcess Resources LLC, is a consulting group specialized in sterilizing filtration, integrity testing and single-use technology. Jornitz has close to 30 years of experience in separation and single-use technologies, the related regulations and validation requirements. Jornitz supports the biopharmaceutical industry on a worldwide basis. As a former member of the PDA Board of Directors (former Chair of the Board of Directors) and member of the Science Advisory Board (SAB), Jornitz has been part of multiple PDA task forces, for example the Technical Report # 26, #40, #41, #45, mycoplasma task forces, and program co-chair for the 2008, 2013 and 2016 Annual Meeting. He is also member of the ISPE, ASTM, ASME, and is faculty member of PDA TRI and Global Compliance. Jornitz authored and co-authored over 100 scientific papers. He is co-editor and author of 9 books for example Filtration and Purification in the Biopharmaceutical Industry, Sterile Filtration — A Practical Approach, Pharmaceutical Filtration and received 5 distinguished author awards, 2 PDA Special Service, the Michael S. Korczynski and Martin Van Trieste award. He has contributed in total 15 chapters to various technical books, including the Encyclopedia of Pharmaceutical Technology. He holds over 30 patents related to biopharmaceutical process equipment (single-use technology) and integrity testing. He formerly worked for Sartorius Stedim in various positions for over 25 years, is Science Advisory Board member of Artemes Technologies and member of the Biotechnology Industry Council. Mr. Jornitz received his M.Eng. in Bioengineering at the University of Applied Sciences in Hamburg, Germany and accomplished the PED program at IMD Business School in Lausanne, Switzerland.